On October 14, 2024, H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc. (Longboard) announced that Lundbeck will acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer to acquire all outstanding shares of Longboard common stock for $60.00 per share in cash. The transaction is valued at approximately $2.6 billion. Wilson Sonsini Goodrich & Rosati advised Evercore, Longboard’s financial advisor, in connection with the transaction.

Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.

The Wilson Sonsini team that advised Evercore on the transaction included Rob Ishii, Doug Schnell, Nikki Smith, and Kaleigh Hawkins-Schulz.

For more information, please see the companies’ news release.